Treatment of retinal vascular disease using progenitor cells

A technology for retinopathy, the retina, applied in the field of cell-based or regenerative therapy, which can solve the problem of destroying healthy tissue and no treatment for dry AMD

Inactive Publication Date: 2019-03-01
JANSSEN BIOTECH INC
View PDF19 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantage of laser therapy is that the high heat energy delivered by the beam also damages adjacent healthy tissue
Neuroscience 4th Edition, (Purves, D et al 2008) states: "There is currently no treatment for dry AMD

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of retinal vascular disease using progenitor cells
  • Treatment of retinal vascular disease using progenitor cells
  • Treatment of retinal vascular disease using progenitor cells

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0068] cell preparation

[0069] Cells, cell populations, and preparations (including cell lysates, conditioned media, etc.) for use in the compositions and methods of the invention are described herein and detailed in U.S. Patent Nos. 7,524,489 and 7,510,873 and U.S. Published Application 2005 / 0058631, each of which is incorporated herein by reference. According to the method using postpartum cells, the mammalian umbilical cord or placenta is recovered at or shortly after the end of a term or preterm pregnancy (eg, after expulsion of the placenta). Postpartum tissue can be transported from the delivery site to the laboratory in sterile containers such as flasks, beakers, petri dishes, or bags. The container may have a solution or medium, including but not limited to, for example, a saline solution such as Dulbecco's Modified Eagle's Medium (DMEM) or Phosphate Buffered Saline (PBS), or any solution used to transport organs for transplantation, such as University of Wiscon...

Embodiment 1

[0163] hUTC efficacy in the rat OIR model

[0164] To study the effect of hUTC on retinal neovascularization.

[0165] Materials and methods

[0166] Human umbilical cord tissue-derived cells (hUTC) are described in Examples 4-16 below and detailed in U.S. Pat. method to obtain. Briefly, human umbilical cords were obtained with the consent of the donor after a live birth. Tissues were minced and digested enzymatically. Using 0.5U / mL collagenase (Serva Elecrtrophoresis, Heidelberg, Germany), 5U / mL neutral protease (Serva Elecrtrophoresis, Heidelberg, Germany) and 2U / mL hyaluronidase (Cumulase; Origio a / s, Denmark) of the mixture of Dalbecco's Modified Eagle's Medium (DMEM)-Low Glucose (Lg) (SAFC Biosciences, Lenexa, KS) after almost complete digestion, the cell suspension was filtered through a 70 μm filter membrane and incubated at 250× g Next centrifuge the supernatant. The detached cells were washed several times in DMEM-Lg and then washed at 5,000 cells / cm 2 was...

Embodiment 2

[0197] Efficacy of hUTC via subretinal injection in the rat OIR model

[0198] To study the effect of subretinal injection of hUTC on retinal neovascularization.

[0199] Materials and methods

[0200] hUTC were obtained as described above in Example 1.

[0201] Sprague Dawley rats were housed from birth to P14 in a variable oxygen atmosphere consisting of 24 h alternating 50% and 10% oxygen events. Upon removal from the oxygen exposure chamber (P14), rats received subretinal injections at two doses / density (4×10 3 or 2×10 4 cells), or vehicle (cryopreservation solution). The treatment group distribution is shown in Table 2-1 below. All pups were sacrificed on day six post-exposure / injection (P20). Pup eyes were enucleated and normal intraretinal vascular growth and abnormal preretinal neovascular growth were assessed on ADPase-stained retinal flat mounts using widely published methods. The area of ​​normal and abnormal vessel growth was measured via computer-aided ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods and compositions for treating ophthalmic disease, reducing retinal neovascularization and retinal vascular leakage using progenitor cells, such as postpartum-derived cells, and conditioned media from the cells, are disclosed.

Description

[0001] Cross References to Related Applications [0002] This patent application claims the benefit of US Provisional Application Serial No. 62 / 358,389, filed July 5, 2016, which is incorporated herein by reference in its entirety. technical field [0003] The present invention relates to the field of cell-based or regenerative therapies for ophthalmic diseases and disorders, particularly ocular conditions such as retinal degenerative disorders. The present invention provides methods and compositions for regenerating or repairing ocular cells and tissues using progenitor cells, such as umbilical cord tissue-derived cells, placental tissue-derived cells, and conditioned media prepared from these cells. Background technique [0004] As a complex and sensitive organ of the human body, the eye is subject to a variety of diseases and other detrimental conditions that affect its ability to function normally. Many of these conditions are associated with damage or degeneration of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/51A61P27/02
CPCA61K35/51A61P27/02A61P43/00A61P9/10C12N5/0605A61K9/0048
Inventor I.哈里斯N.S.德内卡
Owner JANSSEN BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap